Ocriplasmin retinopathy: Possible cause of macular hole closure failure.
A 53 year-old woman with a stage 2 macular hole received ocriplasmin injection as a first approach. She subsequently underwent pars plana vitrectomy due to enlargement of the hole post-injection. The visual gain following the surgery was minimal despite closure of the hole. This could be explained by outer retina atrophy as a consequence of potential toxic mechanisms related to ocriplasmin. Further studies may be warranted to fully understand the impact of ocriplasmin on long-term visual function.